Today’s Solutions: April 21, 2024

Due to a mugging incident, it has been more than 20 years since internationally acclaimed pianist João Carlos Martins has played his beloved instrument with 10 fingers.

But the Brazilian maestro is finally able to play his favorite Bach sonatas once again thanks to innovative “bionic gloves” invented by industrial designer Ubiratan Bizarro.

“When he showed me the gloves, I joked that they were for boxing, not to play the piano,” Martins, 80, said of the unique pair of neoprene gloves, which cost no more than $100 to produce and were made by a 3D printer.

As explained by Reuters, the bionic gloves are equipped with rods that make the fingers spring back up after they depress the keys and allow the pianist to continue playing.

The invention has been a blessing for Martins, who used to perform with leading orchestras in the US and Europe and recorded Bach’s complete keyboards until the injuries, followed by a neurological condition, ended his career.

“To be able to use all ten fingers again more than 20 years later is a miracle for me at the age of 80,” he said.

Bizarro is currently exporting the technology to Europe under the brand name Bionic Extender Gloves and is working to improve the technology so it benefits as many people as possible.

Solutions News Source Print this article
More of Today's Solutions

3 simple ways to save an extra $250 per month

Everyone loves to save money, so here are three easy ways you can free up $250 in your budget per month. Cancel subscriptions you ...

Read More

APA, AAPI, APIDA or AANHPI? The history and significance of the “Asian Americ...

“The journey of a thousand miles begins with one step.” ― Lao Tzu By Arielle Tiangco Weeks ago, seated cross-legged on my couch, I ...

Read More

Playing video games benefit key regions of the brain

A recent study from Georgia State University found that sensorimotor decision-making skills were superior in regular video game players to those that didn’t play ...

Read More

Novel blood cancer treatment effective in three-fourths of trial patients

According to new findings from an ongoing Phase 1/2 clinical research trial, a novel investigational immunotherapy resulted in successful response rates for 73 percent ...

Read More